Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/127987
Título: Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
Autores/as: Obeso, D
Contreras, N
Dolores-Hernández, M
Carrillo Díaz, Teresa 
Barbas, C
Escribese, MM
Villaseñor, A
Barber, D
Clasificación UNESCO: 32 Ciencias médicas
2302 Bioquímica
320701 Alergias
Palabras clave: Allergy
Asthma
Anaphylaxis
Targeted metabolomics
Liquid chromatography coupled to a triple quadrupole mass spectrometry, et al.
Fecha de publicación: 2022
Publicación seriada: Metabolites 
Resumen: The transition from mild to severe allergic phenotypes is still poorly understood and there is an urgent need of incorporating new therapies, accompanied by personalized diagnosis approaches. This work presents the development of a novel targeted metabolomic methodology for the analysis of 36 metabolites related to allergic inflammation, including mostly sphingolipids, lysophospholipids, amino acids, and those of energy metabolism previously identified in non-targeted studies. The methodology consisted of two complementary chromatography methods, HILIC and reversed-phase. These were developed using liquid chromatography, coupled to triple quadrupole mass spectrometry (LC-QqQ-MS) in dynamic multiple reaction monitoring (dMRM) acquisition mode and were validated using ICH guidelines. Serum samples from two clinical models of allergic asthma patients were used for method application, which were as follows: (1) corticosteroid-controlled (ICS, n = 6) versus uncontrolled (UC, n = 4) patients, and immunotherapy-controlled (IT, n = 23) versus biologicals-controlled (BIO, n = 12) patients. The results showed significant differences mainly in lysophospholipids using univariate analyses in both models. Multivariate analysis for model 1 was able to distinguish both groups, while for model 2, the results showed the correct classification of all BIO samples within their group. Thus, this methodology can be of great importance for further understanding the role of these metabolites in allergic diseases as potential biomarkers for disease severity and for predicting patient treatment response.
URI: http://hdl.handle.net/10553/127987
ISSN: 2218-1989
DOI: 10.3390/metabo12070592
Fuente: Metaboliste [2218-1989), v. 12(7) (Junio 2022)
Colección:Artículos
Adobe PDF (2,13 MB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.